The Lancet shared an article by Lucy Marie Carter, et al on X:
“New treatments such as rituximab and belimumab have aided our understanding on treating autoimmune diseases caused by issues with B-cells.
A new Review in The Lancet Rheumatology reflects on 20 years of insights drawn from B-cell targeted therapies.”
Evolution and trajectory of B-cell targeted therapies in rheumatic diseases
Authors: Lucy Marie Carter, Michael R Ehrenstein, Prof Edward M Vital
More posts featuring The Lancet.
